Tharimmune Appoints Jacob Asbury as CFO to Drive Digital Asset Strategy

Written by Emily J. Thompson, Senior Investment Analyst

THAR.O+4.35%

Source: Businesswire

Updated: 1 hour ago

0mins

Source: Businesswire

Executive Appointment: Tharimmune has appointed Jacob Asbury as Chief Financial Officer, overseeing financial strategy and operations, which signifies the company's ongoing commitment to its digital asset strategy.
Extensive Experience: With nearly two decades of financial leadership, including his role as CFO at Clear Street Group, Asbury is expected to drive innovation in the company's financial operations through his deep capital markets background.
Digital Asset Strategy: Tharimmune established its digital asset treasury strategy in November 2025, aiming to enhance market infrastructure by acquiring Canton Coin and applying to operate as a Super Validator.
Market Outlook: Asbury noted that the Canton Network has the potential to transform how financial markets operate, positioning Tharimmune at the forefront of this evolution and committed to creating long-term value for shareholders and the Canton community.

THAR.O

$0.0000%Past 6 months

Line

Candle

YTD

No Data

Intellectia

Analyst Views on THAR

About THAR

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

About the author

Preview

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.